UNSPSC 51373001: Anazocine

This classification denotes an opioid receptor agonist with the molecular formula C16H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K2S5VMM2SG, chemically known as 4-beta-methoxy-1-methyl-4-alpha-phenyl-3-alpha,5-alpha-propanopiperidine but generally known as anazocine, which bears US NIH Compound Identifier 27213. European Medicines Agency schedules Anazocine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05504MIG.

UNSPSC 51373001 Anazocine is a Commodity code that covers pharmaceutical products procured by state and local health agencies, though recent solicitations show activity concentrated in naloxone, drug deactivation systems, and generic multi-source pharmaceuticals rather than anazocine specifically. State and local issuing bodies using this code include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions. Procurement typically takes the form of competitive bids or RFPs for annual supply agreements with quarterly or ongoing delivery schedules, often with two-year initial terms and renewal options. Vendors must comply with Drug Supply Chain Security Act (DSCSA) requirements, current Good Manufacturing Practices (cGMP) certification, FDA compliance, insurance requirements (including workers' compensation and commercial general liability), E-Verify employment verification, and drug-free workplace certification. Contracts frequently include administrative fees, performance penalties for missed delivery or reporting timelines, and probationary periods allowing early termination.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS (due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas Health and Human Services Commission posted RFI HHS0017013 (April 3, 2026) exploring vendor capabilities for direct-to-manufacturer prescription programs outside traditional PBM channels; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products, with awards effective July 1, 2026, distributed through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson). MMCAP's RFP weights price competitiveness at 75 percent and requires vendors to maintain relationships with at least two of three authorized wholesalers with chargeback systems in place.